Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates

First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 ---- Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1 An…